U.K. Crispr And Cas Genes Market Size & Outlook, 2025-2030
- Biotechnology
- Genomics & Genetic Engineering
- CRISPR And Cas Genes Market Outlook
- Genomics & Genetic Engineering
U.K. Crispr And Cas Genes Market, 2018-2030 (US$M)
Global Market
Related Markets
Ask Prism AI anything about the crispr and cas genes market
Get a cited answer from GVR research in seconds: segment shares, growth drivers, regulation and forecast assumptions.
UK crispr and cas genes market highlights
- The UK crispr and cas genes market generated a revenue of USD 268.7 million in 2024 and is expected to reach USD 688.9 million by 2030.
- The UK market is expected to grow at a CAGR of 17.4% from 2025 to 2030.
- In terms of segment, product was the largest revenue generating product & service in 2024.
- Service is the most lucrative product & service segment registering the fastest growth during the forecast period.
Crispr and cas genes market data book summary
| Market revenue in 2024 | USD 268.7 million |
| Market revenue in 2030 | USD 688.9 million |
| Growth rate | 17.4% (CAGR from 2025 to 2030) |
| Largest segment | Product |
| Fastest growing segment | Service |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Product, Service |
| Key market players worldwide | AstraZeneca PLC, Caribou Biosciences Inc Ordinary Shares, Cellectis SA, CRISPR Therapeutics AG, Editas Medicine Inc, Roche Holding AG, PerkinElmer, Genscript Biotech Corp Class H, Danaher Corp, Intellia Therapeutics Inc, Lonza Group Ltd, Merck KGaA, Takara Bio Inc, Thermo Fisher Scientific Inc, Cibus Inc Ordinary Shares - Class A, Beam Therapeutics Inc, Vertex Pharmaceuticals Inc, Addgene, EGenesis, Synthego, Mammoth Biosciences, Inscripta, PLANTEDIT, Hera Biotech, Origene Technologies, Recombinetics |
Other key industry trends
- In terms of revenue, UK accounted for 5.7% of the global crispr and cas genes market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany crispr and cas genes market is projected to lead the regional market in terms of revenue in 2030.
- UK is the fastest growing regional market in Europe and is projected to reach USD 688.9 million by 2030.
In February 2016, the UK became the first country to allow genetic modifications in the embryo, along with permitting the legal replacement of embryonic genes with a third person’s genes. The permissions and grants to improve the research in gene editing are expected to propel growth for CRISPR technology in the UK.
However, the safety of gene editing remains a challenge. For instance, some national agencies have stated that genome editing could be used to cause an outbreak of a dangerous disease. Silence Therapeutics, a UK based company, is taking up projects to implement CRISPR to add genes to mice for protein production.
In January 2019, Horizon Discovery, a UK company, received the license to develop a CRISPR-based gene-editing tool from the U.S.-based Rutgers University. In January 2020, the company collaborated with U.S.-based Mammoth Biosciences to access the latter’s CRISPR platform for development of next-generation engineered CHO cell lines.
No credit card required*
Publish Date: Dec 02, 2024
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
- Turnaround
- 5–10 working days
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
CRISPR And Cas Genes Market Scope
CRISPR And Cas Genes Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Merck KGaA | View profile | 62,345 | Frankfurter Strasse 250, Darmstadt, HE, Germany, 64293 | www.emdgroup.com |
| Lonza Group Ltd | View profile | 18,000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | www.lonza.com |
| Thermo Fisher Scientific Inc | View profile | 122,000 | 168 Third Avenue, Waltham, MA, United States, 02451 | www.thermofisher.com |
| Roche Holding AG | View profile | 103,605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | www.roche.com |
| Danaher Corp | View profile | 63,000 | 2200 Pennsylvania Avenue, N.W., Suite 800W, Washington, DC, United States, 20037-1701 | www.danaher.com |
| Takara Bio Inc | View profile | 1,793 | Nojihigashi 7-4-38 Kusatu, Shiga, Otsu, Japan, 520-0058 | www.takara-bio.co.jp |
| Caribou Biosciences Inc Ordinary Shares | View profile | 137 | 2929 7th Street, Suite 105, Berkeley, CA, United States, 94710 | www.cariboubio.com |
| PerkinElmer | View profile | 10001+ | Waltham, Massachusetts, United States, North America | www.perkinelmer.com |
| AstraZeneca PLC | View profile | 89,900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | www.astrazeneca.com |
| Genscript Biotech Corp Class H | View profile | 6,937 | No. 28, Yongxi Road, Jiangning Science Park, Jiangsu Province, Nanjing, China, People's Republic of, 211100 | www.genscript.com |
U.K. CRISPR And Cas Genes Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to CRISPR And Cas Genes Market Outlook will help companies and investors design strategic landscapes.
Product was the largest segment with a revenue share of 89.06% in 2024.
Horizon Databook has segmented the U.K. crispr and cas genes market based on product, service covering the revenue growth of each sub-segment from 2018 to 2030.
In February 2016, the UK became the first country to allow genetic modifications in the embryo, along with permitting the legal replacement of embryonic genes with a third person’s genes. The permissions and grants to improve the research in gene editing are expected to propel growth for CRISPR technology in the UK.
However, the safety of gene editing remains a challenge. For instance, some national agencies have stated that genome editing could be used to cause an outbreak of a dangerous disease. Silence Therapeutics, a UK based company, is taking up projects to implement CRISPR to add genes to mice for protein production.
In January 2019, Horizon Discovery, a UK company, received the license to develop a CRISPR-based gene-editing tool from the U.S.-based Rutgers University. In January 2020, the company collaborated with U.S.-based Mammoth Biosciences to access the latter’s CRISPR platform for development of next-generation engineered CHO cell lines.
- U.K. Crispr And Cas Genes Market Product & Service Outlook (Revenue, USD Million , 2018-2030)
- Product
- Service
- U.K. Crispr And Cas Genes Market Application Outlook (Revenue, USD Million , 2018-2030)
- Biomedical
- Agricultural
- U.K. Crispr And Cas Genes Market End Use Outlook (Revenue, USD Million , 2018-2030)
- Biotechnology & Pharmaceutical Companies
- Academics & Government Research Institutes
- Contract Research Organizations (CROs)
- Others
Reasons to subscribe to CRISPR And Cas Genes Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of CRISPR And Cas Genes Market Outlook databook
- Our clientele includes a mix of CRISPR And Cas Genes Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.K. CRISPR And Cas Genes Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into U.K. CRISPR And Cas Genes Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.
U.K. Crispr And Cas Genes Market, 2018-2030 (US$M)
UK crispr and cas genes market statistics, by product & service, 2018-2030 (US$M)
